Skip to main content

Table 2 Outcomes of cohort studies

From: Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis

  All cohort studies Only definite nephritis Any SLE patients
Outcome Number of cohorts Number of events/patients Percentage with outcome Number of cohorts Number of events/patients Percentage with outcome Number of cohorts Number of events/patients Percentage with outcome
Efficacy          
Complete or partial response 7 121/151 80 7 121/151 80 No data
Failure/No response 8 37/176 21 7 30/151 20 1 7/25 28
Adverse events          
Adverse event discontinuations 9 40/285 14 4 6/68 8.8 5 34/217 16
Lack of efficacy discontinuations 5 24/235 10 1 4/24 17 4 20/211 9.5
All infections 10 76/327 23 4 18/70 26 6 58/257 23
Serious infections 8 8/185 4.3 4 4/87 4.6 4 4/98 4.1
Gastrointestinal (diarrhoea, nausea, vomiting) 14 122/406 30 8 52/160 33 6 58/257 29
Leucopaenia 8 6/188 3.2 4 1/61 1.6 4 5/127 3.9
Vertigo, dizziness 3 6/81 7.4 No data 3 6/81 7.4
Hair loss 2 5/42 12 1 1/13 7.7 1 4/29 14
  1. SLE, systemic lupus erythematosus.
\